Bpifrance

Superbranche is a biotechnology company focused on the early detection and treatment of metastases through innovative nanotechnological solutions. The company develops therapeutic and diagnostic applications aimed at improving accessibility and enabling the early identification of tumors. Utilizing proprietary technology, Superbranche's platform delivers targeted diagnostic tools and image-guided therapy nanomaterials to clinical settings, enhancing the effectiveness of cancer treatment by allowing for timely interventions. Through its advancements in nanotechnology, Superbranche seeks to transform the landscape of cancer care by prioritizing early detection and personalized treatment strategies.

Vulkam SAS is a microtechnology company based in Saint-Martin-d'Hères, France, specializing in the design and production of amorphous metal parts. Founded in 2017, Vulkam focuses on creating biocompatible amorphous metal alloys primarily composed of zirconium, copper, hafnium, nickel, and titanium. The company's innovative products serve various industries, including aerospace, automotive, biomedical, and microcomponents. Vulkam's micromechanical parts are notable for their small size and exceptional strength, offering performance comparable to established industry standards. By leveraging advanced materials science, Vulkam aims to set new benchmarks in metallurgy and metal processing, catering to the growing demand for high-performance, functional components in diverse applications.

Vulkam SAS is a microtechnology company based in Saint-Martin-d'Hères, France, specializing in the design and production of amorphous metal parts. Founded in 2017, Vulkam focuses on creating biocompatible amorphous metal alloys primarily composed of zirconium, copper, hafnium, nickel, and titanium. The company's innovative products serve various industries, including aerospace, automotive, biomedical, and microcomponents. Vulkam's micromechanical parts are notable for their small size and exceptional strength, offering performance comparable to established industry standards. By leveraging advanced materials science, Vulkam aims to set new benchmarks in metallurgy and metal processing, catering to the growing demand for high-performance, functional components in diverse applications.

Novacium operates as an innovative start-up that specializes in the next generation material development.

Quandela is a company focused on advancing quantum computing technology, specifically in the realms of communication networks and optical computers. It specializes in manufacturing photonic quantum computers, which it supplies to industrial clients. A key innovation from Quandela is its single-photon source device, which integrates photonics with semiconductor quantum dots. This device enables the efficient collection of emitted single photons at high rates, significantly reducing charge noise decoherence and facilitating the emission of identical photons with high fidelity. Such capabilities are essential for the development of advanced quantum applications in communication, computation, and sensing, positioning Quandela as a pivotal player in the quantum technology landscape.

Hummink is a company specializing in additive manufacturing technology, focusing on nano-printing solutions that enable precise design and manufacturing at the nanoscale. Founded in 2020 in Paris by Amin M'barki, Pascal Boncenne, Lydéric Bocquet, Alessandro Siria, and Antoine Nigues, Hummink utilizes a patented technology that integrates a nanometric pen with an oscillating microresonator. This innovative approach allows for the capillary deposition of various liquids, equipping clients in the semiconductor and molecular diagnostic industries with the capability to create large objects while maintaining exceptional resolution and precision on substrates ranging from millimetric to centimetric scales.

Quandela is a company focused on advancing quantum computing technology, specifically in the realms of communication networks and optical computers. It specializes in manufacturing photonic quantum computers, which it supplies to industrial clients. A key innovation from Quandela is its single-photon source device, which integrates photonics with semiconductor quantum dots. This device enables the efficient collection of emitted single photons at high rates, significantly reducing charge noise decoherence and facilitating the emission of identical photons with high fidelity. Such capabilities are essential for the development of advanced quantum applications in communication, computation, and sensing, positioning Quandela as a pivotal player in the quantum technology landscape.

Grapheal is a Medtech startup focused on developing innovative embedded and wearable biosensors designed for modern healthcare applications. Leveraging advanced graphene transistors, Grapheal's devices enable accurate and affordable field diagnostics and remote patient monitoring. Their biosensors, which are minimalistic in design and integrated with wireless connectivity, allow for the precise detection of biomarkers and pathogens, all accessible through a smartphone. The company’s approach encompasses the entire value chain, from synthesizing proprietary sensing nanomaterials to the integration of sensor technology with embedded data analysis and software development, thus facilitating enhanced medical oversight for professionals.

Vulkam SAS is a microtechnology company based in Saint-Martin-d'Hères, France, specializing in the design and production of amorphous metal parts. Founded in 2017, Vulkam focuses on creating biocompatible amorphous metal alloys primarily composed of zirconium, copper, hafnium, nickel, and titanium. The company's innovative products serve various industries, including aerospace, automotive, biomedical, and microcomponents. Vulkam's micromechanical parts are notable for their small size and exceptional strength, offering performance comparable to established industry standards. By leveraging advanced materials science, Vulkam aims to set new benchmarks in metallurgy and metal processing, catering to the growing demand for high-performance, functional components in diverse applications.

NH TherAguix SAS is a clinical-stage pharmaceutical company based in Villeurbanne, France, focused on the development of nanomedicines for cancer treatment. The company specializes in creating innovative therapeutics that enhance radiotherapy for solid tumors. Its lead product, AGuIX, is a theranostic nanoparticle designed to improve the localization of tumors and optimize radiation therapy outcomes. By facilitating intravenous administration, AGuIX enables healthcare professionals to determine the best timing for irradiation, targets tumor tissues more effectively, and minimizes adverse effects on healthy tissues by reducing radiation doses. Founded in 2015, NH TherAguix is dedicated to advancing cancer treatment through its pioneering approach to combining imaging and radiotherapy.

APIX Analytics is a company specializing in the development and marketing of advanced gas analyzer systems. Founded in 2014 and based in Grenoble, France, APIX Analytics focuses on creating miniaturized multigas analyzers using nano-silicon technology. These systems are designed for industrial, environmental, and security applications, integrating analytical chains such as sampling, gas injection, and separation of complex gas mixtures to enhance specificity and detection. The company's technology aims to improve the identification and quantification of each compound in a mixture, thereby increasing safety and quality requirements for various industries, including renewable energy development.

Nanobiotix SA is a clinical-stage biotechnology company based in Paris, France, focused on advancing cancer treatment through its innovative nanomedicine programs. The company is known for its proprietary NanoXray technology, which enhances the effectiveness of radiotherapy by amplifying its impact on tumor cells while minimizing exposure to surrounding healthy tissues. One of its key products, NBTXR3, is a radio-enhancer composed of hafnium oxide designed for treating various solid tumors, including soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, breast cancer, and glioblastoma. Founded in 2003, Nanobiotix is dedicated to transforming cancer therapy and improving patient outcomes using its advanced nanotechnology solutions.

Nanobiotix SA is a clinical-stage biotechnology company based in Paris, France, focused on advancing cancer treatment through its innovative nanomedicine programs. The company is known for its proprietary NanoXray technology, which enhances the effectiveness of radiotherapy by amplifying its impact on tumor cells while minimizing exposure to surrounding healthy tissues. One of its key products, NBTXR3, is a radio-enhancer composed of hafnium oxide designed for treating various solid tumors, including soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, breast cancer, and glioblastoma. Founded in 2003, Nanobiotix is dedicated to transforming cancer therapy and improving patient outcomes using its advanced nanotechnology solutions.

Nanobiotix SA is a clinical-stage biotechnology company based in Paris, France, focused on advancing cancer treatment through its innovative nanomedicine programs. The company is known for its proprietary NanoXray technology, which enhances the effectiveness of radiotherapy by amplifying its impact on tumor cells while minimizing exposure to surrounding healthy tissues. One of its key products, NBTXR3, is a radio-enhancer composed of hafnium oxide designed for treating various solid tumors, including soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, breast cancer, and glioblastoma. Founded in 2003, Nanobiotix is dedicated to transforming cancer therapy and improving patient outcomes using its advanced nanotechnology solutions.